This webinar offers the opportunity to earn self-reporting *CME credits! To register use the form or link, available below! Find your panellists and moderators further down.

Summary & Learning Objectives:

In this roundtable discussion, pathologists Dr. Monroe and Dr. Laser provide an overview of RNAscope technology and how it is shaping the molecular in situ hybridization (ISH) testing landscape. Attendees will see how RNAscope RNA ISH, coupled with automation capability on the BOND platform, takes ISH to the next level.

Through their discussion, you will:

• Understand the significance of ISH and its traditional role in diagnostic testing as a valuable tool for obtaining a comprehensive diagnostic picture.
• Learn about the evolution of ISH, focusing on how RNAscope technology has successfully progressed the capabilities of traditional ISH through its potential to provide higher sensitivity and specificity in RNA detection.
• See the ISH difference for yourself as RNAscope is put into context and comes alive with slide images. You will see how the technology allows for highly specific target recognition and amplification of RNA signals.

Upon registering, attendees are welcome to leave questions for the panel before the webinar. We look forward to seeing you there and answering your questions at the Live Q and A to follow!

Speaker Biographies:

Jordan Laser, M.D. is a board certified anatomic, clinical and molecular genetic pathologist with a wide range of professional experiences in both academia, health systems as well as industry. Currently employed at Bio-Techne, Jordan is responsible for clinical and medical affairs related to the diagnostic solutions provided by the clinical laboratory facing brands within the company. Prior to that, Jordan continued his journey in patient empowerment while working at Everly Health, a consumer-initiated-physician-ordered laboratory company by providing patients direct access to laboratory tests. Finally, for over a decade, Jordan was a clinical leader in the Department of Pathology and Laboratory Medicine at Northwell Health in NY. His responsibilities included system-wide leadership of point of care testing, cytogenetics and molecular pathology as well as site directorship of tertiary hospital and reference laboratories. His expertise includes molecular and genomic medicine, laboratory management, healthcare finance and standards and regulations.Robert Monroe, M.D., Ph.D., board-certified in Cytopathology, Anatomic Pathology, and Clinical Pathology with a PhD in Genetics, assumed roles as the VP and Chief Scientific Officer of Oncology at Danaher Diagnostics and CMO at Leica Biosystems in 2022, enhancing their molecular oncology initiatives. His previous roles include CMO at Bio-Techne, BioImagine, a digital pathology startup acquired by Roche, and OncoMDx, a molecular diagnostics lab he co-founded and was later acquired by Core Diagnostics in 2012. Monroe also served as VP at Veracyte and practiced pathology in California, following his medical and residency training at Harvard, UCLA, and Stanford.

Moderator:

Jack Heath, PhD Medical Science Liaison

*Leica Biosystems makes no guarantee or assurances that the educational content will in any manner ensure achievement of credits for continuing education. Please check with your own certifying organization(s) and agencies to determine continuing education, licensure, and recertification requirements.